USPTO Patent Application: Allosteric Modulators for CRPC Therapy
Summary
The USPTO has published a patent application (US20260083751A1) from the University of Pittsburgh detailing allosteric modulators of the androgen receptor for treating castration-resistant prostate cancer (CRPC). The application describes small molecule compounds that may inhibit androgen receptor coactivator recruitment.
What changed
This document is a USPTO patent application (US20260083751A1) filed by the University of Pittsburgh. It discloses small molecule allosteric modulators of the androgen receptor, designed to inhibit coactivator recruitment and potentially treat castration-resistant prostate cancer (CRPC). The application details the chemical compounds and a method of treatment.
As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in CRPC therapeutics, which may be of interest to pharmaceutical companies and researchers in the oncology space. No immediate actions are required for compliance officers.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ALLOSTERIC MODULATORS OF ANDROGEN RECEPTOR COACTIVATOR RECRUITMENT FOR CRPC THERAPY
Application US20260083751A1 Kind: A1 Mar 26, 2026
Assignee
University of Pittsburgh – Of the Commonwealth System of Higher Education
Inventors
Paul A. Johnston, Andrew P. Hinck, Carlos J. Camacho, Peter Wipf, Zhou Wang, Lee A. McDermott
Abstract
Small molecule allosteric modulators of androgen receptor are disclosed. The compounds may inhibit androgen receptor coactivator recruitment, such as by preventing formation of protein-protein interaction (PPI) complexes and/or disrupting PPI complexes. A method of treating prostate cancer, such as castration-resistant prostate cancer, includes administering a small molecule allosteric modulator of androgen receptor.
CPC Classifications
A61K 31/553 A61K 31/4045 A61K 31/4155 A61K 31/4439 A61K 31/454 A61K 31/497 A61K 31/501 A61P 35/00
Filing Date
2023-08-30
Application No.
19108095
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.